Search
People living with Type 1 diabetes (T1D) can participate in all forms of physical activity, but it can sometimes be a little more challenging.
Check out the Centre's video library here
Our goal is to accelerate the dissemination and implementation of evidence-based models of care for children and young people living with Type 1 Diabetes.
A new research study conducted by Professor Jeneva Ohan and Dr Keely Bebbington aims to develop our understanding of how adolescents navigate these disclosure decisions, and how we can support them to feel more confident when talking to others about their diabetes.
Besides the challenges associated with their teenage years, adolescents with Type 1 Diabetes (T1D) encounter additional challenges of having a chronic condition.
To assess relationships between continuous glucose monitoring (CGM) time in range (TIR), 70-180 mg/dL, time below range (TBR), <70 mg/dL, time above range (TAR), >180 mg/dL, and glucose coefficient of variation (CV) in relation to currently recommended clinical CGM targets for older people, which recommend reduced TIR and TBR targets relative to the general type 1 diabetes population.
Type 1 diabetes is well-recognised as a continuum heralded by the development of islet autoantibodies, progression to islet autoimmunity causing beta cell destruction, culminating in insulin deficiency and clinical disease. Abnormalities of glucose homeostasis are known to exist well before the onset of typical symptoms.
Advanced hybrid closed-loop (AHCL) therapy with the Medtronic MiniMed™ 780G system improves glycemia; however, the clinical outcomes in younger children remain less established. This pilot study aimed to explore the continuous glucose monitoring (CGM) metrics in very young children on AHCL. Children between 2 and 7 years of age and on insulin pump therapy were recruited.
Glycemia risk index (GRI) is a novel composite metric assessing overall glycemic risk, accounting for both hypoglycemia and hyperglycemia and weighted toward extremes. Data assessing GRI as an outcome measure in closed-loop studies and its relation with conventional key continuous glucose monitoring (CGM) metrics are limited.